Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables

The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1

(2017) Jay M Sosenko et al.   PEDIATRIC DIABETES

Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA 1c , and Insulin Dose

(2016) Wei Hao et al.   DIABETES CARE

A model-based approach to sample size estimation in recent onset type 1 diabetes

(2016) Brian N. Bundy et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report

(2015) Diane K. Wherrett et al.   DIABETES CARE

Partial Remission Definition: Validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish Children with New-Onset Type 1 Diabetes

(2014) Marie Louise C Max Andersen et al.   PEDIATRIC DIABETES

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

(2013) K. C. Herold et al.   DIABETES

The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients

(2013) Jay M. Sosenko et al.   DIABETES CARE

Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study

(2013) A. Barker et al.   DIABETES OBESITY & METABOLISM

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

(2013) Antoinette Moran et al.   LANCET

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

(2013) Mark R Rigby et al.   Lancet Diabetes & Endocrinology

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

(2013) Stephen E Gitelman et al.   Lancet Diabetes & Endocrinology

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

(2012) C. J. Greenbaum et al.   DIABETES

Primary and secondary prevention of Type 1 diabetes

(2012) J. S. Skyler   DIABETIC MEDICINE

The T1D Exchange Clinic Registry

(2012) Roy W. Beck et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insulin-Pump Therapy for Type 1 Diabetes Mellitus

(2012) John C. Pickup   NEW ENGLAND JOURNAL OF MEDICINE

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

(2011) Diane K Wherrett et al.   LANCET

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

Failure to Preserve  -Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes

(2010) P. A. Gottlieb et al.   DIABETES CARE

New Definition for the Partial Remission Period in Children and Adolescents With Type 1 Diabetes

(2009) H. B. Mortensen et al.   DIABETES CARE

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of  -Cell Function in Therapeutic Trials in Type 1 Diabetes

(2008) C. J. Greenbaum et al.   DIABETES CARE